pembrolizumab,toripalimab,nivolumab,ipilimumab,Atezolizumab,durvalumab,pemetrexed,carboplatin,paclitaxel,vinorelbine,nab-paclitaxel,cisplatin,docetaxel,gemcitabine
merck,Roche,BMS,Coherus,Junshi Biosciences,Astrazeneca
['kn671']
. discusses kn671. overviews current data. os hrs seem better for neoadjuv vs adj but 15 20% won t make surgery: we don t really know why. role of adj post neo suggests some benefit cf 816 &amp; agean if no pcr. rapid ngs critical. great overview #asco23 
Thoracic Oncologist @royalmarsdenNHS, Professor @ICR_London; Chair @BTOGorg; views are my own.